All In Biotech

Drug Trial Radar · NCT00202644

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.

Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jan 13, 2006

Primary completion

Dec 15, 2015

Study completion Dec 15, 2015

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots. When patients have too many platelets, there is a risk of blood clots forming unnecessarily and excessive bleeding. The aim of this study is to gain additional information on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as hydroxycarbamide).

Conditions

  • Thrombocythemia, Hemorrhagic

Interventions

  • AnagrelideDrug

    Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.

  • HydroxyureaDrug

    Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over TimeTime frame: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36
  2. Platelet Count at Month 6Time frame: Month 6

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven

    Pleven, Bulgaria

  • University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic

    Varna, Bulgaria

  • Hopital Saint Louis - Centre d'Investigation Clinique

    Paris, France

  • CHU Angers Services des Maladies du Sang

    Angers, Cedex 09, France

  • University of Debrecen Medical and Health Science Centre

    Debrecen, Hungary

  • Petz Aladar County Teaching Hospital

    Győr, Hungary

  • Pandy Kalman Hospital of Bekes County

    Gyula, Hungary

  • Kaposi Mor Teaching Hospital

    Kaposvár, Hungary

  • Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii

    Gdansk, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 1

    Lublin, Poland

  • Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej

    Warsaw, Poland

  • Klinika Hematologii Instytut Hematologii i Transfuzjologi

    Warsaw, Poland

  • Hospitals da Universidade de Coimbra

    Coimbra, Portugal

  • Institute for Haematology of Clinical Centre of Serbia

    Belgrade, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.